Qube Research & Technologies (QRT)’s Cardiff Oncology CRDF Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$163K	Buy	+125,550	New	+$199K	﹤0.01%	2948
2024 Q4	–	Sell	-37,245	Closed	-$99.4K	–	3505
2024 Q3	$99.4K	Sell	37,245 -3,419	-8%	-$8.08K	﹤0.01%	2745
2024 Q2	$90.3K	Sell	40,664 -86,619	-68%	-$326K	﹤0.01%	2626
2024 Q1	$680K	Buy	127,283 +127,231	+244,675%	+$338K	﹤0.01%	2369
2023 Q4	$77	Hold	52	–	–	﹤0.01%	4043
2023 Q3	$72	Buy	+52	New	+$88	﹤0.01%	3788
2022 Q4	–	Sell	-29,996	Closed	-$46K	–	2547
2022 Q3	$46K	Sell	29,996 -3,042	-9%	-$7.32K	﹤0.01%	2152
2022 Q2	$73K	Buy	+33,038	New	+$55.3K	﹤0.01%	2039
2021 Q3	–	Sell	-15,335	Closed	-$102K	–	2292
2021 Q2	$102K	Sell	15,335 -45,312	-75%	-$384K	﹤0.01%	1946
2021 Q1	$562K	Sell	60,647 -35,798	-37%	-$435K	0.01%	1109
2020 Q4	$1.74M	Buy	+96,445	New	+$1.7M	0.02%	670

Other funds holding CRDF

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Qube Research & Technologies (QRT)'s CRDF Position: Q2 2026 in Review

Qube Research & Technologies (QRT) opened a new position in Cardiff Oncology (CRDF) in Q2 2026: 125,550 shares worth $163K. The stake represents ﹤0.01% of the portfolio and ranks #2948 among its holdings. This is a return to the name: Qube Research & Technologies (QRT) previously reported a position in CRDF as recently as Q3 2024.

Qube Research & Technologies (QRT) first reported a position in CRDF in Q4 2020 and has held it in 11 quarters since. The position peaked at $1.74M in Q4 2020. 105 funds tracked by Wall St. Rank hold CRDF as of Q2 2026.

Qube Research & Technologies (QRT) held 125,550 shares of Cardiff Oncology worth $163K as of Q2 2026.
Cardiff Oncology was a new Qube Research & Technologies (QRT) position in Q2 2026.
Cardiff Oncology made up ﹤0.01% of Qube Research & Technologies (QRT)'s portfolio in Q2 2026, its #2948 holding.
Qube Research & Technologies (QRT) first reported a position in Cardiff Oncology in Q4 2020 and has held it in 11 quarters since.
Qube Research & Technologies (QRT)'s Cardiff Oncology position peaked at $1.74M in Q4 2020.
105 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.